Trials are initiated by the sponsor (Cytodyn in this case) and typically outsourced to a CRO…Cytodyn doesn’t need to be the size of Pfizer to pull this off they just need capital. For that they have passed the hat to plebes like me and other investors but they could easily find some weighty jingle under the debris created by Amarex, or through partnership funding. In my book it doesn’t really matter…money flows to opportunity and Leronlimab should have tractor-beam level influence in that regard with the data which has surfaced in already completed trials.